Lonza
sees no delays for COVID-19 vaccine project, citing
Trump backing
Send a link to a friend
[July 24, 2020]
By John Miller
ZURICH (Reuters) - Swiss drugmaker Lonza sees no delays for its project
to make Moderna's COVID-19 vaccine candidate and has "strong support"
from U.S. President Donald Trump to get the necessary manufacturing
equipment, its chairman said.
|
Chairman Albert Baehny had earlier raised concerns that hiring
qualified staff and finding gear like bioreactors on short notice
could snarl aggressive goals to begin commercial manufacturing of
vaccine ingredients for Moderna.
Lonza is readying production of smaller batches this month for
Moderna's mRNA vaccine trials in 30,000 people.
Baehny told reporters he remains confident he will find workers and
the equipment he needs to complete commercial manufacturing
facilities this year in Portsmouth, New Hampshire, and early next
year in Visp, Switzerland.
"We are doing very well having access to the people, we can build up
the teams in Portsmouth and in Visp to manufacture in the future
these drug substances," he said.
"There are basically no major issues in equipment, it's a bit more
complicated than the people, but I don't think we'll be facing
delays because of delays in equipment delivery, as we see it today,"
he said. "We have strong support from the Trump administration to
have access to the equipment, as well."
[to top of second column] |
Baehny made the comments as Lonza reported a rise in first-half sales and profit
and unveiled plans to begin selling its speciality ingredients unit in the
second half of 2020.
Lonza is exiting chemicals to focus on its faster-growing drugs business that
has a 10-year deal with Moderna to make ingredients for its drugs, including the
vaccine candidate.
First-half profit rose 22% to 478 million Swiss francs ($517 million) on
increasing demand from biotech customers. Sales rose 3.3% to 3.1 billion francs,
matching consensus estimates.
(Reporting by John Miller; Editing by John Revill, Stephen Coates and Emelia
Sithole-Matarise)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|